Background-Biomarker activation in atrial fibrillation (AF) has been widely studied, but the immediate effect of AF initiation remains unclear. We studied the effect of AF initiation on 2 cardiac biomarkers: the N-terminal fragment of the proB-type natriuretic peptide (NT-proBNP), the midregional fragment of the N-terminal of pro-atrial natriuretic peptide (MR-proANP), and 2 extracardiac biomarkers-the copeptin and the midregional portion of proadrenomedullin (MR-proADM). Methods and Results-This was a randomized controlled study, including 45 patients with AF who had been referred for radiofrequency ablation to the University Hospital, Link_ oping, Sweden, between February 2012 and April 2014. Freedom from AF during the 4 days prior to rad...
AIM: Supraventricular tachyarrhythmias, most frequently atrial fibrillation (AF), occur in 8-30% of ...
Background: RFA is a well-established treatment for symptomatic patients with AF. However, the succe...
AimsChange in NT-proBNP level is a common surrogate endpoint in early phase heart failure (HF) trial...
Background-Biomarker activation in atrial fibrillation (AF) has been widely studied, but the immedia...
Atrial fibrillation (AF) is the most common cardiac arrhythmia. In order to improve the management o...
Background There is limited knowledge on the short‐term influence of radiofrequency ablation (RFA) o...
Objective Atrial fibrillation (AF) is the most common cardiac arrhythmia, and radiofrequency cathete...
Background To investigate the effects of catheter ablation and rate control strategies on cardiac an...
Abstract Background Catheter ablation is an established therapy for atrial fibrillation but is limit...
Introduction: Atrial fibrillation (AF) is the most common form of sustained cardiac arrhythmia. AF r...
The role of B-type natriuretic peptide (BNP) levels as a predictor of arrhythmia recurrence (AR) aft...
<div><p>Background</p><p>Different biological pathways have been related to atrial fibrillation (AF)...
Background: Atrial fibrillation (AF) frequently impairs quality of life, but in long-term it is asso...
Atrial fibrillation (AF) is an independent predictor of mortality after acute myocardial infarction ...
AbstractN-terminal proB-type natriuretic peptide (NT-proBNP) is known as a marker of heart failure (...
AIM: Supraventricular tachyarrhythmias, most frequently atrial fibrillation (AF), occur in 8-30% of ...
Background: RFA is a well-established treatment for symptomatic patients with AF. However, the succe...
AimsChange in NT-proBNP level is a common surrogate endpoint in early phase heart failure (HF) trial...
Background-Biomarker activation in atrial fibrillation (AF) has been widely studied, but the immedia...
Atrial fibrillation (AF) is the most common cardiac arrhythmia. In order to improve the management o...
Background There is limited knowledge on the short‐term influence of radiofrequency ablation (RFA) o...
Objective Atrial fibrillation (AF) is the most common cardiac arrhythmia, and radiofrequency cathete...
Background To investigate the effects of catheter ablation and rate control strategies on cardiac an...
Abstract Background Catheter ablation is an established therapy for atrial fibrillation but is limit...
Introduction: Atrial fibrillation (AF) is the most common form of sustained cardiac arrhythmia. AF r...
The role of B-type natriuretic peptide (BNP) levels as a predictor of arrhythmia recurrence (AR) aft...
<div><p>Background</p><p>Different biological pathways have been related to atrial fibrillation (AF)...
Background: Atrial fibrillation (AF) frequently impairs quality of life, but in long-term it is asso...
Atrial fibrillation (AF) is an independent predictor of mortality after acute myocardial infarction ...
AbstractN-terminal proB-type natriuretic peptide (NT-proBNP) is known as a marker of heart failure (...
AIM: Supraventricular tachyarrhythmias, most frequently atrial fibrillation (AF), occur in 8-30% of ...
Background: RFA is a well-established treatment for symptomatic patients with AF. However, the succe...
AimsChange in NT-proBNP level is a common surrogate endpoint in early phase heart failure (HF) trial...